{"id":65707,"date":"2026-05-19T23:12:21","date_gmt":"2026-05-19T15:12:21","guid":{"rendered":"https:\/\/flcube.com\/?p=65707"},"modified":"2026-05-19T23:12:23","modified_gmt":"2026-05-19T15:12:23","slug":"cspc-pharmaceutical-receives-nmpa-clinical-trial-approval-for-syh2095-worlds-first-kat6-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65707","title":{"rendered":"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World&#8217;s First KAT6 Inhibitor"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced it has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>SYH2095<\/strong>, a <strong>Category 1 chemical drug<\/strong> and <strong>novel inhibitor of lysine acetyltransferase 6 (KAT6)<\/strong>. This milestone positions SYH2095 as the <strong>world&#8217;s first-in-class therapeutic<\/strong> targeting the KAT6 pathway, with preclinical studies demonstrating <strong>potent anti-tumor activity<\/strong>, <strong>favorable pharmacokinetics<\/strong>, and a <strong>good safety profile<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-product-classification\">Regulatory Milestone &amp; Product Classification<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (Category 1 innovative drug)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SYH2095 (oral small molecule)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Lysine acetyltransferase 6 (KAT6)<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>First-in-class; no approved drugs targeting this pathway worldwide<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novel-mechanism-of-action\">Novel Mechanism of Action<\/h2>\n\n\n\n<p><strong>SYH2095<\/strong> represents a <strong>groundbreaking approach<\/strong> to epigenetic cancer therapy:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Target<\/strong>: <strong>Lysine acetyltransferase 6 (KAT6)<\/strong>, a key epigenetic regulator<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Inhibits <strong>acetylation of histone lysine<\/strong>, leading to <strong>chromatin condensation<\/strong><\/li>\n\n\n\n<li><strong>Downstream Effects<\/strong>: Regulates <strong>cell cycle progression<\/strong>, <strong>estrogen receptor expression<\/strong>, and <strong>cellular senescence pathways<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Disrupts fundamental epigenetic processes driving tumor growth and survival<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence-amp-drug-profile\">Preclinical Evidence &amp; Drug Profile<\/h2>\n\n\n\n<p>Comprehensive preclinical studies have established SYH2095&#8217;s compelling profile:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Potency<\/strong>: Demonstrates <strong>potent and selective inhibition of KAT6<\/strong> with high target specificity<\/li>\n\n\n\n<li><strong>Efficacy<\/strong>: <strong>Significantly suppresses tumor growth<\/strong> in multiple preclinical models<\/li>\n\n\n\n<li><strong>Pharmacokinetics<\/strong>: Exhibits <strong>favorable PK properties<\/strong> supporting once-daily oral dosing<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Shows <strong>good safety profile<\/strong> with wide therapeutic window in animal studies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage<\/strong>: As the <strong>world&#8217;s first KAT6 inhibitor<\/strong> to enter clinical development, CSPC enjoys substantial competitive moats<\/li>\n\n\n\n<li><strong>Epigenetic Therapy Market<\/strong>: Global epigenetic drugs market projected to reach <strong>$15 billion by 2030<\/strong>, with novel targets commanding premium valuations<\/li>\n\n\n\n<li><strong>Unmet Medical Need<\/strong>: KAT6 pathway implicated in multiple solid tumors and hematological malignancies with limited treatment options<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: First-in-class status supports <strong>blockbuster potential<\/strong> with premium pricing and broad indication expansion opportunities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-cspc-pharmaceutical\">Strategic Implications for CSPC Pharmaceutical<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Leadership<\/strong>: Validates CSPC&#8217;s transformation from traditional pharmaceutical manufacturer to <strong>innovative drug developer<\/strong><\/li>\n\n\n\n<li><strong>Global Ambitions<\/strong>: First-in-class status provides strong foundation for <strong>international partnerships<\/strong> and <strong>global regulatory filings<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Diversification<\/strong>: Adds high-value targeted therapy to CSPC&#8217;s oncology portfolio<\/li>\n\n\n\n<li><strong>Valuation Catalyst<\/strong>: Category 1 designation and first-in-class status likely to re-rate investor perception of CSPC&#8217;s innovation capabilities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-indications-amp-therapeutic-potential\">Target Indications &amp; Therapeutic Potential<\/h2>\n\n\n\n<p>While specific indications were not disclosed, KAT6 biology suggests potential in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hormone-Responsive Cancers<\/strong>: Estrogen receptor regulation suggests activity in <strong>breast and ovarian cancers<\/strong><\/li>\n\n\n\n<li><strong>Cell Cycle-Dependent Tumors<\/strong>: Cell cycle progression effects may benefit <strong>hematological malignancies<\/strong> and <strong>solid tumors<\/strong> with cell cycle dysregulation<\/li>\n\n\n\n<li><strong>Senescence-Related Cancers<\/strong>: Cellular senescence pathway modulation could address <strong>therapy-resistant tumor populations<\/strong><\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Epigenetic mechanism may synergize with <strong>existing targeted therapies<\/strong> and <strong>immunotherapies<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-next-steps\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase I Initiation<\/strong>: Expected to begin <strong>Q3-Q4 2026<\/strong> with dose escalation and safety assessment<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong>: NMPA approval enables rapid Chinese clinical development while supporting <strong>parallel FDA\/EMA interactions<\/strong><\/li>\n\n\n\n<li><strong>Partnership Potential<\/strong>: Strong preclinical data and first-in-class status likely to attract <strong>strategic partnership interest<\/strong> from global pharmaceutical companies<\/li>\n\n\n\n<li><strong>Market Exclusivity<\/strong>: Category 1 designation provides <strong>extended data exclusivity<\/strong> and <strong>patent protection<\/strong> in China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Novelty<\/strong>: KAT6 represents <strong>untapped therapeutic target<\/strong> with strong biological validation<\/li>\n\n\n\n<li><strong>Mechanistic Innovation<\/strong>: Epigenetic approach addresses <strong>fundamental cancer biology<\/strong> rather than downstream signaling<\/li>\n\n\n\n<li><strong>Selectivity Advantage<\/strong>: High selectivity for KAT6 may reduce <strong>off-target toxicity<\/strong> compared to broader epigenetic modulators<\/li>\n\n\n\n<li><strong>Platform Potential<\/strong>: Success validates CSPC&#8217;s <strong>epigenetic drug discovery platform<\/strong> for additional targets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for SYH2095. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051801493_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051801493_c.\"><\/object><a id=\"wp-block-file--media-5adbb591-140f-490e-a6e3-5fae3fca2d55\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051801493_c.pdf\">2026051801493_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051801493_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5adbb591-140f-490e-a6e3-5fae3fca2d55\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,171,855],"class_list":["post-65707","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World&#039;s First KAT6 Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for SYH2095, a Category 1 chemical drug and novel inhibitor of lysine acetyltransferase 6 (KAT6). This milestone positions SYH2095 as the world&#039;s first-in-class therapeutic targeting the KAT6 pathway, with preclinical studies demonstrating potent anti-tumor activity, favorable pharmacokinetics, and a good safety profile.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65707\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World&#039;s First KAT6 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for SYH2095, a Category 1 chemical drug and novel inhibitor of lysine acetyltransferase 6 (KAT6). This milestone positions SYH2095 as the world&#039;s first-in-class therapeutic targeting the KAT6 pathway, with preclinical studies demonstrating potent anti-tumor activity, favorable pharmacokinetics, and a good safety profile.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65707\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T15:12:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T15:12:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65707#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65707\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World&#8217;s First KAT6 Inhibitor\",\"datePublished\":\"2026-05-19T15:12:21+00:00\",\"dateModified\":\"2026-05-19T15:12:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65707\"},\"wordCount\":590,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65707#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65707\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65707\",\"name\":\"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World's First KAT6 Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-19T15:12:21+00:00\",\"dateModified\":\"2026-05-19T15:12:23+00:00\",\"description\":\"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for SYH2095, a Category 1 chemical drug and novel inhibitor of lysine acetyltransferase 6 (KAT6). This milestone positions SYH2095 as the world's first-in-class therapeutic targeting the KAT6 pathway, with preclinical studies demonstrating potent anti-tumor activity, favorable pharmacokinetics, and a good safety profile.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65707#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65707\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65707#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World&#8217;s First KAT6 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World's First KAT6 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for SYH2095, a Category 1 chemical drug and novel inhibitor of lysine acetyltransferase 6 (KAT6). This milestone positions SYH2095 as the world's first-in-class therapeutic targeting the KAT6 pathway, with preclinical studies demonstrating potent anti-tumor activity, favorable pharmacokinetics, and a good safety profile.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65707","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World's First KAT6 Inhibitor","og_description":"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for SYH2095, a Category 1 chemical drug and novel inhibitor of lysine acetyltransferase 6 (KAT6). This milestone positions SYH2095 as the world's first-in-class therapeutic targeting the KAT6 pathway, with preclinical studies demonstrating potent anti-tumor activity, favorable pharmacokinetics, and a good safety profile.","og_url":"https:\/\/flcube.com\/?p=65707","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T15:12:21+00:00","article_modified_time":"2026-05-19T15:12:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65707#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65707"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World&#8217;s First KAT6 Inhibitor","datePublished":"2026-05-19T15:12:21+00:00","dateModified":"2026-05-19T15:12:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65707"},"wordCount":590,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65707#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65707","url":"https:\/\/flcube.com\/?p=65707","name":"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World's First KAT6 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-19T15:12:21+00:00","dateModified":"2026-05-19T15:12:23+00:00","description":"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for SYH2095, a Category 1 chemical drug and novel inhibitor of lysine acetyltransferase 6 (KAT6). This milestone positions SYH2095 as the world's first-in-class therapeutic targeting the KAT6 pathway, with preclinical studies demonstrating potent anti-tumor activity, favorable pharmacokinetics, and a good safety profile.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65707#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65707"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65707#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World&#8217;s First KAT6 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65707"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65707\/revisions"}],"predecessor-version":[{"id":65709,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65707\/revisions\/65709"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}